We use cookies to improve user experience, and analyze website traffic.
For these reasons, we may share your site usage data with our analytics partners. By clicking "Accept Cookies" you consent to store on your device all the technologies described in our Cookie Policy.
Reports Q4 revenue $25.7M, consensus $13.92M. As of December 31, 2022, Cellectis, excluding Calyxt, had $95M in consolidated cash, cash equivalents, and restricted cash vs. $177M as of December 31, 2021. "In 2022, Cellectis presented positive preliminary clinical data from five additional patients from its BALLI-01 trial evaluating UCART22 in patients with r/r B-cell ALL. The results showed evidence of UCART22 anti-tumor activity observed in three of the first five patients (60%) that were treated at DL3. Overall, these preliminary data support the continued administration of UCART22 after FCA lymphodepletion in patients with r/r B-cell ALL. We are excited by these preliminary clinical responses for the patients who have limited, if any, treatment options, especially for those who have failed prior CD19 directed CAR T-cell therapy and allogeneic stem cell transplant. UCART22 is currently the most advanced allogeneic CAR T-cell product in development for ALL.." said CEO Andre Choulika....This year, Cellectis remains deeply focused on the patient recruitment of its four ongoing Phase 1 clinical trials BALLI-01, AMELI-01, MELANI-01 and NATHALI-01 evaluating UCART22, UCART123, UCARTCS1 and UCART20x22 respectively".
Cellectis S.A. announced the launch of a global offering of $22M of its American Depositary Shares, ADS, each representing one ordinary share of Cellectis pursuant to an underwriting agreement, to be entered into by Cellectis, Jefferies and Barclays Capital. The company plans to use the net proceeds of the offering to fund the continued clinical development of UCART123, UCART22, UCART20x22, and UCARTCS1, and for working capital and other general corporate purposes. Jefferies and Barclays Capital are acting as joint book-running managers for the offering.
JMP Securities analyst Silvan Tuerkcan lowered the firm's price target on Cellectis to $6 from $11 but keeps an Outperform rating on the shares as part of a broader research note on select Biotechnology names updating his valuation models. SMID-cap companies, particularly with less cash runway, are finally urgently focusing their pipelines and operations on key assets, but while this is a positive longer-term, workforce reductions are "unfortunately accelerating", the analyst tells investors in a research note. Tuerkcan adds that he sees Cellectis' CAR-T targets as a key differentiator to bispecifics and many other alloCARTs in development.
Cellectis (CLLS) announced that Cibus Global and Calyxt (CLXT), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein, pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. The transaction combines two companies in agriculture-based gene editing, with facilities for trait development and next-generation plant breeding. Cellectis currently holds a 49.1% equity interest in Calyxt. Following the closing of the merger, Cellectis is expected to own approximately 2.5% of the equity interests of the combined company. In connection with the Merger Agreement, Cellectis executed a voting agreement with Cibus to vote in favor of and approve all the transactions contemplated by the Merger Agreement, subject to the terms and conditions thereof. The closing of the transaction is subject to the approval of Calyxt's stockholders, the approval of Cibus' members, the receipt of required regulatory approvals and satisfaction of other customary closing conditions. In connection with the transaction, Calyxt will file a registration statement on Form S-4 with the U.S. Securities and Exchange Commission, registering the issuance of the shares of common stock to be issued as merger consideration. The closing of the transaction is currently expected to occur in the second quarter of 2023.
The company states: "Following the formation of Mayflower Bioventures, a cell and gene therapy accelerator stood up from Hibiscus BioVentures and Mayo Clinic, comes the launch of their first start-up, Primera Therapeutics, Inc. Cellectis and Primera announced today the execution of a Collaboration Agreement under which the Parties will work collaboratively to edit mutations in the mitochondrial DNA in vivo to treat the root cause of associated diseases. Inherited mitochondrial diseases caused by genetic changes in the mtDNA have very limited to no treatment options, and often result in early childhood death. An estimated 1 in 5,000 people worldwide suffer from mtDNA - associated diseases. Primera is advancing pioneering mtDNA gene editing therapies developed in the Mayo Clinic lab of Drs. Steven Ekker and Karl Clark to precisely fix a patient's mutated mtDNA and potentially achieve a cure for the disease. Primera's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments. Mayo Clinic excels in delivering and developing advanced care for complex diseases including the interdisciplinary research and clinical treatment through its Mitochondrial Care Research Center."
Cellectis "announced that it has entered into a EUR 40 million credit facility agreement with the European Investment Bank, or EIB. The company plans to use the facility toward the development of its pipeline in the field of allogeneic CAR T-cell product candidates, UCART22, UCART20x22, UCART123 and UCARTCS1."
